Qiagen (QGEN) said its Digital Insights bioinformatics business will integrate Nvidia's (NVDA) accelerated computing and BioNeMo platform to support researchers using AI for drug discovery.
The integration is intended to help pharmaceutical and biotechnology researchers to better understand disease biology and identify therapeutic targets and biomarkers, the company said Tuesday in a statement.
Qiagen said initial pilot programs will be available to select pharmaceutical and biotechnology partners, with broader availability expected after validation.
Financial details weren't disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments